Profile data is unavailable for this security.
About the company
AbbVie Inc. is a research-based biopharmaceutical company, which is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. It offers products in various therapeutic categories, including immunology products, which include Humira, Skyrizi and Rinvoq; oncology products, which include Imbruvica and Venclexta; aesthetics products that include Botox Cosmetic, Juvederm Collection and others; neuroscience products, such as Botox Therapeutic, Vraylar, Duopa and Duodopa, and Ubrelvy; eye care products consists of Lumigan, Alphagan and Restasis; women's health products include Lo Loestrin, Orilissa and others; and other products, which includes Mavyret, Creon, Lupron, Linzess and Synthroid. Its products are sold to wholesalers, government agencies, health care facilities and independent retailers. It also discovers and develop antibody medicines that target difficult-to-drug disease-causing proteins, such as G protein-coupled receptors (GPCRs).
- Revenue in USD (TTM)57.82bn
- Net income in USD13.34bn
- LocationAbbvie Inc1 N Waukegan RdNORTH CHICAGO 60064United StatesUSA
- Phone+1 (847) 932-7900
- Fax+1 (302) 655-5049
Mergers & acquisitions
|Acquired company||Deal status||Date||Date /|
|ABBV:NYQ since |
|DJS Antibodies Ltd||Deal completed||20 Oct 2022||20 Oct 2022Deal completed||13.92%||255.00m|
|iSTAR Medical SA||Announced||20 Jul 2022||20 Jul 2022Announced||8.90%||475.00m|
|Syndesi Therapeutics SA||Deal completed||01 Mar 2022||01 Mar 2022Deal completed||10.35%||1.00bn|